Home / Expertise / Life Sciences & Healthcare

Life Sciences & Healthcare

Netherlands

We work for top 100 enterprise. For example farmaceutical companies ranked in the global top 20. Furthermore, nine out of ten of the global producers of medical instruments are part of our client base. To our lawyers – who often have an in-house history in your industry themselves – your industry has no secrets. The marketing of medicinal products. Public procurement. Pricing and reimbursement. The protection of patents. Or agreements for clinical trials. We know what you are talking about. That is why we assist our top clients with their strategic decisions, the structuring of their business transactions and in legal proceedings.

Our experts, many of whom have worked in-house in your sector, have developed a shared capability in the areas of pharmaceuticals, biotechnology and medical devices. With active memberships in major industry associations such as the ABPI, ABHI, BIVDA, PAGB, EUCOMED and EFPIA, we help shape the legal frameworks impacting the lifesciences sector. We regularly advise our clients on their day-to-day operational needs such as support with advertisement and promotion of medicine, public sector procurement, pricing and reimbursement, patent enforcement, commercial and clinical trial agreements as well as regulatory advice. Equally, when you need lifesciences specialist advice for strategic agreements, planning a corporate transaction or embarking on litigation (whether product liability or otherwise), we have a team that is well versed in the industry issues to help you.

Read more Read less

"Really efficient and quick."

Chambers Global, 2020

"The firm is a reliable international firm that has shown us a deep knowledge of the applicable law and significant practical experience on relevant cases."

Chambers Global, 2020

"Extremely responsive and overall always felt that I was in extremely safe hands."

Chambers Global, 2019

"They are very well connected with their team; they really use the benefit of working together in their various offices."

Chambers Global, 2019

A client describes the lawyers as "subject matter experts".

Chambers Europe, 2019

Clients praise the firm's international network as a key advantage, particularly appreciating that "it is able to provide expertise across multiple jurisdictions. This co-operation is done in a very expedient and uncomplicated manner."

Chambers Europe, 2019

"The CMS team offers a broad range of expertise including regulatory, IP, and competition."

The Legal 500, 2019

In M&A the firm has a good reputation for working in the hospitality, life sciences and oil and gas sectors.

IFLR1000, 2019

"The client service and responsiveness are exceptional."

Chambers Europe, 2018

Choose area

    Pharmaceuticals

    Pharmaceutical and healthcare law focuses on all the special legislation and legal aspects to do with medicine provision, biotechnology and healthcare. Whether it concerns manufacturing, operations, licences, rates, quality, market regulation or care insurance, there is specific legislation for all these areas.

    Read more
    02/04/2019
    WLG Can­nabis Leg­al­iz­a­tion: Europe Up­date
    Pod­cast
    Sub­scribe to Life Sci­ences & Health­care top­ics
    September 2019
    CMS Life Sci­ences & Health­care Glob­al Bro­chure

    Feed

    Show only
    05 Dec 19
    A leg­al roadmap for Can­nabis 2019
    26 Feb 20
    Can­nabis mark ruled con­trary to pub­lic policy
    Back­ground On 19 Decem­ber 2016, Ms Santa Conte (“Ms Conte”) made an ap­plic­a­tion to re­gister an EU trade mark for the fol­low­ing fig­ur­at­ive sign in re­la­tion to vari­ous food and drink products and ser­vices...
    June 2018
    De­liv­er­ing qual­ity ad­vice you can act on
    An­nu­al Re­view 2017 – 2018
    31 Jan 20
    UK In­tel­lec­tu­al Prop­erty Of­fice finds that pat­ent law does not cater...
    The UK In­tel­lec­tu­al Prop­erty Of­fice has found that DABUS is not a per­son and so can­not be con­sidered an in­vent­or of a pat­ent. DABUS is an ar­ti­fi­cial in­tel­li­gence (AI) ma­chine. The UKIPO ac­cep­ted the in­dic­a­tion...
    CMS Ex­pert Guide to a Leg­al Roadmap to Can­nabis
    17 Jan 20
    New guid­ance on cy­ber­se­cur­ity for med­ic­al devices pub­lished
    In Decem­ber 2019, the Med­ic­al Device Co­ordin­a­tion Group (“MD­CG”) is­sued a new guid­ance to help med­ic­al device man­u­fac­tur­ers meet the cy­ber­se­cur­ity re­quire­ments in the Med­ic­al Devices Reg­u­la­tion (“MDR”)...
    15 Jan 20
    Can newly dis­covered can­nabis com­pounds be pro­tec­ted by pat­ents?
    A break­through dis­cov­ery has re­cently hit the news: tet­rahy­drocan­nabi­phorol (THCP) and can­na­bid­i­phorol (CB­DP), two new can­nabin­oid com­pounds, have been dis­covered in Can­nabis sativa and char­ac­ter­ised...
    05 Nov 19
    Whis­tleblow­ing Dir­ect­ive ad­op­ted by the EU Coun­cil
    On 7 Oc­to­ber 2019, the EU Coun­cil ap­proved the word­ing of the "Dir­ect­ive of the European Par­lia­ment and of the Coun­cil on the pro­tec­tion of per­sons who re­port breaches of Uni­on law", also known as the...
    13 Sep 19
    SPC Double Whammy - In­ter­pret­ing Art­icle 3(a) of the SPC Reg­u­la­tion
    Sum­mary At the end of June, the CJEU heard the joint re­fer­rals from the Ger­man Bundes­pat­ent­gericht (case C-650/17) for Mer­ck’s sitaglipt­in product and from the Eng­lish Court of Ap­peal for Searle’s...
    24 Aug 18
    Gov­ern­ment Is­sues Brexit Tech­nic­al No­tice for Life Sci­ences
    On 23 Au­gust 2018, the UK Gov­ern­ment (the "Gov­ern­ment") is­sued the first wave of its tech­nic­al pa­pers de­signed to provide guid­ance to com­pan­ies to help pre­pare for a "No Deal" Brexit. In this scen­ario,...
    21 Jun 17
    The Ver­dict - Round-up of cor­por­ate crime de­vel­op­ments across CMS
    We are pleased to send our new is­sue of The Ver­dict, an at-a-glance round-up of re­cent leg­al de­vel­op­ments in re­la­tion to cor­por­ate crime. In this is­sue, the spot­light is on some sig­ni­fic­ant changes...
    10 Feb 17
    In­dia Budget 2017 - 2018
    On 1 Feb­ru­ary, Fin­ance Min­is­ter Ar­un Jait­ley presen­ted In­dia’s an­nu­al Uni­on Budget for 2017-2018 (the “Budget”) for the fisc­al year be­gin­ning 1 April 2017. The cent­ral aim in this year’s Budget...